Skip to content

Eva Lhotková

8 papers in the library · 103 citations · publishing 2016-2026

Papers

Sort Most recent Most cited

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention

Addiction Biology March 1, 2026 Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.

Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-administration (IVSA). Rats were trained on...

DOI: 10.1111/adb.70111 (opens in new tab) Psilocybin Extinction optical mineralogy Hallucinogen Drug +2

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation.

Frontiers in Pharmacology 2023 Kateřina Syrová, Klára Šíchová, Hynek Danda et al. 4 citations

Introduction: N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe...

DOI: 10.3389/fphar.2023.1120419 (opens in new tab) Full text (opens in new tab) 2c-b-fly-nbome Nbome series New psychoactive substance Pharmacokinetics +10

Naphyrone (naphthylpyrovalerone): Pharmacokinetics, behavioural effects and thermoregulation in Wistar rats

Addiction Biology May 7, 2020 Nikola Pinterová, Rachel R. Horsley, Hynek Danda et al. 13 citations

Naphthylpyrovalerone (naphyrone) is a pyrovalerone cathinone that potently inhibits monoamine transporters and provides stimulatory-entactogenic effects. Little is known about the safety of naphyrone or its effects in vivo, and more research is needed to acquire knowledge about its fundamental effects on physiology and behaviour. Our objective was to investigate naphyrone's pharmacokinetics,...

DOI: 10.1111/adb.12906 (opens in new tab) Pharmacokinetics Pharmacology Open field In vivo +4

Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat

Frontiers in Psychiatry April 24, 2018 Rachel R. Horsley, Eva Lhotková, Kateřina Hájková et al. 20 citations

3,4-methylenedioxypyrovalerone (MDPV) is a potent pyrovalerone cathinone that is substituted for amphetamines by recreational users. We report a comprehensive and detailed description of the effects of subcutaneous MDPV (1-4 mg/kg) on pharmacokinetics, biodistribution and metabolism, acute effects on thermoregulation under isolated and aggregated conditions, locomotion (open field) and sensory...

DOI: 10.3389/fpsyt.2018.00144 (opens in new tab) Pharmacokinetics Pharmacology Thermoregulation Cathinone +6

Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats

Frontiers in Psychiatry January 10, 2018 Klára Šíchová, Nikola Pinterová, Monika Židková et al. 28 citations

Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open...

DOI: 10.3389/fpsyt.2017.00306 (opens in new tab) Pharmacology Mephedrone Pharmacokinetics Drug

Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.

European Neuropsychopharmacology December 2017 Tomáš Hložek, Libor Uttl, Lukáš Kadeřábek et al.

Metabolic and behavioural effects of, and interactions between Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are influenced by dose and administration route. Therefore we investigated, in Wistar rats, effects of pulmonary, oral and subcutaneous (sc.) THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h,...

DOI: 10.1016/j.euroneuro.2017.10.037 (opens in new tab) Full text (opens in new tab) Behaviour Cannabidiol CBD Pharmacokinetics δ9-Tetrahydrocannabinol THC

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Brain Research Bulletin May 4, 2016 Rachel R. Horsley, Eva Lhotková, Kateřina Hájková et al. 38 citations

Methoxetamine (MXE) is a novel psychoactive compound (NPS) that emerged in 2010 as a substitute for the dissociative anaesthetic ketamine. MXE has a reputation of carrying a lower risk of harm than ketamine, however a number of deaths have been reported. Currently very little is known about the psychopharmacological effects of this compound or its toxicity; therefore we tested, in Wistar rats,...